-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

Benzinga·11/10/2026 14:15:58
Listen to the news
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.